Supplementary material 1: individual patient data from the discovery cohort. Supplementary material 2: supplementary results; table S1: Prevalence of MGMT promoter methylation and MGMT variants patients from the Discovery cohort; table S2: Multivariate Cox regression model for overall survival (OS) in patients from the discovery cohort that received chemotherapy; table S3: Multivariate Cox regression model for OS, including MGMT variants or promoter methylation in patients from the discovery cohort that did not receive chemotherapy; table S4: Multivariate Cox regression model for progression-free survival (PFS), including MGMT variants or promoter methylation and TP53 variants in patients from the discovery cohort that received chemotherapy; table S5: Multivariate Cox regression model for PFS, including MGMT variants or promoter methylation in patients from the discovery cohort that did not receive chemotherapy; table S6: Multivariate Cox regression model for PFS, including AGT variants and MGMT variants or promoter methylation in patients from the discovery cohort; table S7: Validation cohort multivariate Cox regression model. Supplementary material 3: details and annotations of variants detected in the discovery cohort. Supplementary material 4: clinical data of patients from the validation cohort (TCGA). Supplementary material 5: Annotation of AGT, MGMT and TP53 variants from the validation cohort. Supplementary material 6: REMARK checklist for this work. Supplementary material 7: supplementary methods; Primers used in MGMT gene promoter methylation status assessment.